Minimal Survival Differences Among RT Modalities for Intermediate-Risk PCa
In a study, brachytherapy was associated with only a slight survival advantage over dose-escalated EBRT.
Radiotherapy
Doubling of Radical Surgery Rates for High-Risk Prostate Cancer Reported
By 2016, radical prostatectomy use nearly equaled radiation therapy use for high-risk prostate cancer.
Prostate Cancer Therapy Options Have Similar Cost-Effectiveness, Study Finds
Given that the findings do not show major differences between care options in prostate cancer, cost probably shouldn’t be a major factor driving decision making.
ADT Use Enables Delay in Prostate Cancer Radiation Therapy
Radiation therapy for higher-risk prostate cancer can be delayed for up to 6 months following initiation of hormonal therapy without incurring a greater mortality risk, a finding that has implications for patient care during the COVID-19 pandemic.
Radiation Therapy After Prostate Surgery Worsens Sexual, Urinary Function
Allowing an approximately 24-month recovery period after prostate surgery before giving radiation therapy may be optimal for preserving erectile function provided oncologic control is not compromised, according to investigators.
Restructured Process Overcomes Barriers to Prior Authorization for Proton Therapy
This study examined the impact of a restructured prior authorization process on the delivery of PBT at a proton therapy center.
Perirectal Hydrogel Spacer May Reduce Prostate Radiotherapy Rectal Toxicities
Injection of a hydrogel spacer to provide prostate-rectum separation during radiation therapy for prostate cancer is associated with decreased radiation-induced rectal toxic effects, according to a new systematic review and meta-analysis.
Intensity-Modulated Radiation Charges for Prostate Cancer Vary
Mean charge for standard 28-fraction was $111,728.80, 10.1 times the price paid by Medicare.
Prostate Cancer Treatment Side Effects Worse With Prostatectomy
In a study, localized prostate cancer patients reported clinically meaningful differences in urinary, bowel, sexual, and hormonal function by management option up to 5 years of follow-up.
Adding Chemo to Radiation Treatment for MIBC Does Not Worsen HRQoL
Findings from a large study of bladder-sparing treatments for muscle-invasive bladder cancer support the routine use of 5-fluorouracil and mitomycin C concomitantly with radiation therapy.
-
Loading...
-
Loading...
Next post in Bladder Cancer
